IMNM
Price
$8.58
Change
+$0.18 (+2.14%)
Updated
Apr 28 closing price
Capitalization
746.56M
9 days until earnings call
SYRE
Price
$14.67
Change
+$0.54 (+3.82%)
Updated
Apr 28 closing price
Capitalization
884.24M
9 days until earnings call
Ad is loading...

IMNM vs SYRE

Header iconIMNM vs SYRE Comparison
Open Charts IMNM vs SYREBanner chart's image
Immunome
Price$8.58
Change+$0.18 (+2.14%)
Volume$778.84K
Capitalization746.56M
Spyre Therapeutics
Price$14.67
Change+$0.54 (+3.82%)
Volume$550.93K
Capitalization884.24M
IMNM vs SYRE Comparison Chart
Loading...
IMNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMNM vs. SYRE commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a Buy and SYRE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (IMNM: $8.58 vs. SYRE: $14.67)
Brand notoriety: IMNM and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNM: 66% vs. SYRE: 72%
Market capitalization -- IMNM: $746.56M vs. SYRE: $884.24M
IMNM [@Biotechnology] is valued at $746.56M. SYRE’s [@Biotechnology] market capitalization is $884.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNM’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • IMNM’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, IMNM is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNM’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • IMNM’s TA Score: 6 bullish, 3 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, IMNM is a better buy in the short-term than SYRE.

Price Growth

IMNM (@Biotechnology) experienced а +7.25% price change this week, while SYRE (@Biotechnology) price change was +8.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.10%. For the same industry, the average monthly price growth was -2.09%, and the average quarterly price growth was -11.07%.

Reported Earning Dates

IMNM is expected to report earnings on Aug 13, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($884M) has a higher market cap than IMNM($747M). IMNM YTD gains are higher at: -19.209 vs. SYRE (-36.985). IMNM has higher annual earnings (EBITDA): -151.35M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. IMNM (217M). SYRE has less debt than IMNM: SYRE (0) vs IMNM (4.83M). IMNM has higher revenues than SYRE: IMNM (9.04M) vs SYRE (0).
IMNMSYREIMNM / SYRE
Capitalization747M884M85%
EBITDA-151.35M-208.57M73%
Gain YTD-19.209-36.98552%
P/E RatioN/A1.68-
Revenue9.04M0-
Total Cash217M603M36%
Total Debt4.83M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
78
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMNMSYRE
RSI
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
81%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 21 days ago
87%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Ad is loading...
IMNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X94978.7500001223.914100
+1.31%
Bitcoin cryptocurrency
GME27.590.13
+0.47%
GameStop Corp
AAPL210.140.86
+0.41%
Apple
TSLA285.880.93
+0.33%
Tesla
SPY550.850.21
+0.04%
SPDR® S&P 500® ETF

IMNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYMR. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNM
1D Price
Change %
IMNM100%
+2.14%
KYMR - IMNM
55%
Loosely correlated
+1.05%
IDYA - IMNM
54%
Loosely correlated
+3.95%
BEAM - IMNM
53%
Loosely correlated
+1.43%
RXRX - IMNM
52%
Loosely correlated
+1.92%
CCCC - IMNM
51%
Loosely correlated
+5.19%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+3.82%
BEAM - SYRE
53%
Loosely correlated
+1.43%
CGON - SYRE
52%
Loosely correlated
+25.03%
APGE - SYRE
51%
Loosely correlated
+2.55%
IMNM - SYRE
49%
Loosely correlated
+2.14%
ACLX - SYRE
49%
Loosely correlated
+1.32%
More